New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.
about
Polymyxins and quinazolines are LSD1/KDM1A inhibitors with unusual structural featuresComparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.In Vitro activities of combinations of rifampin with other antimicrobials against multidrug-resistant Acinetobacter baumannii.Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis.Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocolSubstantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.Colistin: efficacy and safety in different populations.Polymyxin B versus colistin: an update.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.Urinary Concentrations of Colistimethate and Formed Colistin after Intravenous Administration in Patients with Multidrug-Resistant Gram-Negative Bacterial Infections.Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.Dosing guidance for intravenous colistin in critically-ill patients.The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study.Clinical Pharmacokinetics and Pharmacodynamics of Colistin.Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance.Colistin and neurotoxicity: recommendations for optimal use in cystic fibrosis patients.Colistin Pharmacokinetics in Pediatrics.Dose suggestions for intravenous colistin in pediatric patients: Caution required.
P2860
Q28595992-AD9FF195-F73C-42F1-ACAC-6673C4B4C5E3Q34597749-41813628-8BC2-49E1-9786-3711CAEA4674Q35076951-177BAAD8-18C6-4133-9492-3DC08DAF0746Q36290841-BD20F76C-BBF9-484A-BD48-F984EFBB8A61Q36644676-5FCAC722-4E4A-4130-9131-DDCF2FFC95CAQ36818945-6FCF1732-719B-4FFB-86A1-FEE5C371FB83Q37538748-209114A3-E509-4E4E-AFA2-DED34940D717Q38514980-99330B35-7553-477A-8846-3C68F9997A44Q38613051-977B4FFF-7FCF-4048-AB68-BF90F0CF34A2Q38672016-46933162-5829-494A-A9F9-21C91D72FDBAQ38677017-D491648F-824F-4F01-9A7F-6391ACCA6EA9Q38944862-1BE24AFF-32E3-41A8-B360-011CB606787EQ39067724-407FA667-E588-44B7-A64F-045754553411Q39236424-E074102D-B1F8-48B0-A476-B1BCDC5E0B44Q39333751-53018BD4-9A53-4CE8-B881-EE23AD1F0D48Q40719307-E008AE10-E9C9-4DBC-88C2-7D3C5C499854Q40911068-15AF63AD-48A0-4F2F-9AB8-112B3E8D2B3DQ50049557-6D5759E3-6587-4347-869C-8D1F25019B22Q50049561-1B2DAD4F-FFE7-40BD-B0EA-A382CF06834D
P2860
New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
New colistin population pharma ...... native loading dose rationale.
@ast
New colistin population pharma ...... native loading dose rationale.
@en
type
label
New colistin population pharma ...... native loading dose rationale.
@ast
New colistin population pharma ...... native loading dose rationale.
@en
prefLabel
New colistin population pharma ...... native loading dose rationale.
@ast
New colistin population pharma ...... native loading dose rationale.
@en
P2093
P2860
P50
P356
P1476
New colistin population pharma ...... rnative loading dose rationale
@en
P2093
P2860
P304
P356
10.1128/AAC.03508-14
P407
P577
2014-09-29T00:00:00Z